Biological effect markers for exposure to carcinogenic compound and their relevance for risk assessment

In this review data are summarized on biomarkers that are used for biological effect monitoring of human populations exposed to genotoxic carcinogens. The biomarkers are DNA and protein adducts and cytogenetic effects. Most of these biomarkers are relevant for the process of carcinogenesis. Emphasis is on providing information on the properties of the biomarkers and on their relevance for predicting cancer risk. Overviews are presented of: (1) studies on effects of exposure in target tissues of human origin obtained by surgical biopsies or autopsies, (2) epidemiological studies on healthy (cancer-free) individuals, correlating the putative occupational, lifestyle or environmental exposure with increased levels of biomarkers in blood cells, and (3) studies with animal models on the relation between biomarkers and cancer. Finally, on the basis of epidemiological data the possibilities were explored to use biomarker data to estimate the risk of death due to cancer. For several biomarkers the increment of the cancer mortality risk was calculated on the basis of a lifetime doubling of the biomarker level

Comparison of the X-gal- and P-gal-based systems for screening of mutant λlacZ phages originating from the transgenic mouse strain 40.6

The recent introduction of the phenyl-β-D-galactopyranoside (P-gal)-based positive-selection system for screening of λlacZ phages originating from the λlacZ transgenic mouse (Muta Mouse) has made the determination of mutant frequencies (MF) a much simpler task. Previously, MF data from these mice have been collected by means of the 5-bromo-4-chloro-3- indolyl-β-D-galactopyranoside (X-gal) colour-screening procedure. To determine whether data obtained with the two systems are comparable, the MF in h phages recovered from liver and brain of transgenic mice treated with N-ethyl-N-nitrosourea (ENU) and liver of benzo(a)pyrene (B(α)P)-treated mice was determined with both procedures. For the livers of mice treated with ENU, both methods yielded approximately the same MF values. No induction of mutants, relative to the control animals, was seen after 1.5 h, but a clear 4-fold increase was measured with both assays at the 14-day time point. No induction of mutants was found in the brain with either method. In the B(α)P-treated mice, both methods showed a substantial induction in MF after 21, 28 and 35 days. The values generated by the X-gal and P-gal methods were not significantly different, with the exception of the 35-day post-treatment point that appeared higher in the X-gal assay. When the mutants isolated by use of the X-gal method were tested in the P-gal assay, a number of these did not turn up as mutants, and the significance disappeared, In conclusion, the data obtained with the two screening procedures agree to such an extent as to permit a direct comparison between the earlier results generated with X-gal and P-gal values generated with the new positive-selection method. This is likely to apply also to other organs and mutagens than those studied here

DNA adducts, mutant frequencies and mutation spectra in λlacZ transgenic mice treated with N-nitrosodimethylamine

Groups of λlacZ transgenic mice were treated i.p. with N-nitrosodimethylamine (NDMA) as single doses of 5 mg/kg or 10 mg/kg or as 10 daily doses of 1 mg/kg and changes in DNA N7- or O6-methylguanine or the repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT) were followed for up to 14 days in various tissues. Adduct induction in the liver exceeded by at least one order of magnitude than observed in the next nearest target tissue (lung), and was approximately linearly related to dose, except for O6-methylguanine after the first dose of 1 mg/kg which was lower than expected. Substantial induction of λlacZ mutagenesis was observed only in the liver, where the mutant frequency was already maximal within 7 days after 5 mg/kg NDMA and remained unchanged thereafter up to 49 days. Small but marginally significant increases in mutant frequency were consistently observed in the spleen after all three modes of treatment. A lack of proportionality between mutation induction and the administered dose or the corresponding adduct levels was observed, probably reflecting the importance of toxicity-related cell proliferation caused by NDMA at higher doses. Twenty eight days after a dose of 10 mg/kg (causing a 3.6-fold increase in mutant frequency), NDMA was found to increase the frequency of GC→AT mutations (with a concomitant shift of their preferential location from CpG sites to GpG sites), which made up ~ 60% of the induced mutations. Surprisingly, NDMA also caused a significant increase in deletions of a few (up to 11) base-pairs (22%)